Medtronic (NYSE:MDT – Get Free Report) had its price objective lowered by equities research analysts at Robert W. Baird from $93.00 to $85.00 in a research report issued on Thursday,Benzinga reports. The firm presently has a “neutral” rating on the medical technology company’s stock. Robert W. Baird’s target price suggests a potential upside of 8.86% from the stock’s current price.
A number of other research firms have also recently commented on MDT. Evercore set a $106.00 price target on shares of Medtronic and gave the company an “outperform” rating in a report on Thursday, April 9th. Truist Financial cut their price target on shares of Medtronic from $103.00 to $95.00 and set a “hold” rating on the stock in a report on Wednesday, April 15th. Daiwa Securities Group dropped their target price on shares of Medtronic from $117.00 to $115.00 and set a “buy” rating on the stock in a report on Friday, February 27th. Wall Street Zen cut shares of Medtronic from a “buy” rating to a “hold” rating in a report on Saturday, April 11th. Finally, Barclays raised their target price on shares of Medtronic from $118.00 to $120.00 and gave the stock an “overweight” rating in a report on Wednesday, April 1st. Sixteen research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $102.38.
View Our Latest Report on Medtronic
Medtronic Trading Up 5.9%
Medtronic (NYSE:MDT – Get Free Report) last posted its quarterly earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.01. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The firm had revenue of $9.81 billion for the quarter, compared to analysts’ expectations of $9.62 billion. During the same quarter in the prior year, the company posted $1.62 earnings per share. The business’s revenue for the quarter was up 9.9% on a year-over-year basis. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. On average, equities research analysts forecast that Medtronic will post 5.54 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in the business. DV Trading LLC raised its position in Medtronic by 190.0% in the first quarter. DV Trading LLC now owns 2,900 shares of the medical technology company’s stock worth $251,000 after acquiring an additional 1,900 shares during the period. Parallel Advisors LLC raised its position in Medtronic by 2.7% in the first quarter. Parallel Advisors LLC now owns 24,856 shares of the medical technology company’s stock worth $2,154,000 after acquiring an additional 663 shares during the period. Optiver Holding B.V. raised its position in Medtronic by 366.9% in the first quarter. Optiver Holding B.V. now owns 677 shares of the medical technology company’s stock worth $59,000 after acquiring an additional 532 shares during the period. First Nebraska Trust Co bought a new position in Medtronic in the first quarter worth approximately $6,009,000. Finally, Ipsen Advisor Group LLC raised its position in Medtronic by 2.5% in the first quarter. Ipsen Advisor Group LLC now owns 6,101 shares of the medical technology company’s stock worth $529,000 after acquiring an additional 149 shares during the period. 82.06% of the stock is currently owned by institutional investors.
Medtronic News Roundup
Here are the key news stories impacting Medtronic this week:
- Positive Sentiment: Medtronic topped Q4 expectations with revenue of $9.81 billion and adjusted EPS of $1.55, supported by strong demand in cardiovascular devices and standout growth in Cardiac Ablation Solutions, which jumped 78% globally. Article Title
- Positive Sentiment: Management said FY2026 delivered Medtronic’s strongest annual revenue growth in 10 years, while FY2027 guidance calls for 6.75% to 7.25% organic revenue growth and EPS of $5.90 to $6.00, reinforcing the company’s growth outlook. Article Title
- Positive Sentiment: Medtronic also raised its quarterly dividend to $0.72 per share, a signal of confidence in cash flow and shareholder returns. Article Title
- Positive Sentiment: The company highlighted momentum in its Hugo robotic surgery platform and new strategic investments in cardiac ablation technologies, which could support longer-term growth and product expansion. Article Title
- Neutral Sentiment: Wall Street reacted positively even though some investors remain focused on tariff pressures, margin headwinds, and FY2027 EPS guidance that came in slightly below the consensus estimate. Article Title
About Medtronic
Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.
Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).
Featured Articles
- Five stocks we like better than Medtronic
- Dell’s AI Toll Bridge Is Paved with Record Margins
- As AI Data Breaches Become More Common, This Cybersecurity ETF Is SurgingAI
- Coke’s $10B India IPO Plan Pops the Top on Hidden Value
- FedEx Unboxes Billions in Post-Spinoff Value
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.
